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Hereditary hemochromatosis (HH) is the most 
commonly identified autosomal recessive genetic 
disorder in the white population, characterized by 
increased intestinal iron absorption and secondary 
abnormal accumulation in parenchymal organs, not 
infrequently accompanied by functional impairment.1 
This entity is associated with mutations of the HFE gene 
(located on the short arm of chromosome 6 at location 
6p22.2; closely linked to the HLA-A3 locus), which 
encodes the HFE protein, a membrane protein thought 
to regulate iron absorption by affecting the interaction 
between transferrin receptor and transferrin. One of 
these mutations results in a substitution of tyrosine 
for cysteine at the amino acid 282 position (C282Y).2,3 
Subsequently two additional mutations have been 
noted, aspartate for histidine (H63D), and cysteine 
for serine (S65C), however the most common form 
of HFE-related HH is associated with the C282Y 
homozygous mutation.4 The presence of this mutation 
varies between 69% to 100% in series from USA, 
France, Italy, Australia, Germany.5-9 Other HFE defects 
in addition to homozygosity for C282Y, are found: 
homozygosity for the H63D mutation, heterozygosity 
for the C282Y or H63D mutation, or compound 
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heterozygosity.10 Less commonly, the hemojuvelin, 
hepcidin, ferroportin, or ceruloplasmin encoding genes 
may also be associated with HH.
There is a substantial controversy on the likelihood 
of homozygous patients for C282Y developing clinically 
apparent diseased. In a USA screening study involving 
41,000 adults, 152 individuals were positive for 
C282Y homozygosity, but only one fit the criteria for 
the diagnosis of HH (penetrance < 1%).11 In contrast, 
the Australian series of 31,192 subjects of northern 
European ancestry found 203 C282Y homozygous. 
These individuals were followed for 12 years, with 
28% of men and 1,2% or women presenting with 
clinical HH.12
Once thought to be a rare disease, HH was initially 
considered when the patient presented an unusual 
manifestation such as “bronze diabetes”. Indeed 
the first case description by Armand Trousseau, in 
1865, was of a diabetic patient with hepatic cirrhosis 
and bronzed skin. The name hemochromatosis was 
applied in subsequent 1890 report by Daniel von 
Recklinghausen. Recklinghausen suggested the 
association between tissue iron storage and the 
resultant condition. The image above shows well the 
brown discoloration of the liver and also the pancreas, 
the body of which is almost mahogany. The inherited 
nature of the disease was first explained by J.H. 
Sheldon in his textbook Haemochromatosis. He also 
suggested an abnormality of iron metabolism as the 
basis for the disease.
With genetic studies, families have been accurately 
studied showing that transferrin saturation values 
greater than 60% in men and greater than 50% 
in women (in the absence of hepatopathy of any 
etiology) indicates the presence of abnormality in iron 
metabolism with 95% accuracy. In the USA and Europe 
the frequency of HFE mutations among Caucasian is 
10% for heterozygous and 5 per 1000 (0.5%) for 
homozygous.13
Body iron stores inversely correlate with the normal 
intestinal absorption of heme and non-heme iron. In 
HH this regulation is lost and iron overload ensues since 
there is no mechanism for excess excretion. Clinical 
symptoms appear when greater than 20g of iron is 
accumulated in the body, typically occurring after the 
age of 40 in men and, when menstruation occurs, 
50 in women. Differing from acquired (secondary) 
hemosiderosis, HH iron is initially stored in parenchymal 
cells and later in the reticuloendothelial system cells.
The clinical picture reflects the involvement of 
liver, skin, pancreas, joints, and heart, with impotence 
in males.14 Liver function abnormalities, weakness 
and fatigue, and skin hyperpigmentation were 
present in more than 70% of cases in the series by 
Niederau et al14.
Liver involvement manifests as hepatomegaly, 
increasing fibrosis and eventual cirrhosis, potentially 
reversible in early stages. Although infection with 
hepatitis-C virus may potentiate fibrosis, the major 
risk co-factor for the development of liver disease is 
excess alcohol intake. The deposition of iron alone in 
hepatocytes is not inflammatory and hepatic fibrosis 
may ensue with low or normal serum aminotransferase 
determinations.15,16 However in almost 50% of patients 
with HH, another cause of liver disease is present that 
is more likely responsible for hepatic liver enzyme 
elevations. Hepatocellular carcinoma is the most 
serious complication of the hepatic iron overload. 
The magnitude of the risk varies between 20- to 200-
fold.17,18
Pancreatic deposition of iron occurs in beta cells 
and diabetes is clinically demonstrable in 50% of 
symptomatic patients. Although insulin and C-peptide 
secretion are reduced, the alpha cell function remains 
intact, and glucagon values are similar to those in 
type-1 diabetes.19
HH can lead to dilated cardiomyopathy, heart 
failure and conduction disturbances, such as sick sinus 
syndrome.20,21
Arthritis associated with HH clinically resembles 
rheumatoid arthritis with predominant involvement of 
metacarpophalangeal joints. The iron deposition within 
the joints triggers an inflammatory process that is often 
complicated by calcium pyrophosphate deposition 
(“pseudogout”) and subsequent chondrocalcinosis 
and chronic arthropathy.22-24
Secondary hypogonadism, responsible for 
impotence and decreased libido in men, is the result 
of iron deposition in the anterior pituitary, which 
results in low levels of trophic hormones (e.g., follicle 
stimulating hormone) and therefore testosterone. 
Amenorrhea rarely occurs in women and is much less 
common than hypogonadism in men.25,26
The  d iagnos t i c  workup  o f  HH inc ludes 
determination of iron overload (increased body 
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iron burden), family history of this disorder and 
genetic studies. In addition to serum iron assay, liver 
biopsy and magnetic resonance imaging studies are 
usually employed. However liver biopsy is often not 
performed for patients with HH when the diagnosis 
is clearly established based upon genetic testing, 
including findings of C282Y/C282Y, heterozygous 
C282Y, and C282Y/H63D genotypes. The findings 
of H63D homozygosity or heterozygosity is of 
uncertain significance since most will not present iron 
overload.27,28
Keywords: hemochromatosis, Iron Overload, Liver 
Diseases, Pancreatic Disease.
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